PRECLINICAL BEMCENTINIB AND TILVESTAMAB DATA PRESENTED AT EAU 2021
Bergen, Norway, 10 July 2021 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that preclinical data from a study investigating the anti-tumor efficacy of BerGenBio’s AXL-inhibitors bemcentinib and tilvestamab in renal cell carcinoma (RCC) was presented at the European Association of Urology 2021 virtual congress. Data from the study, conducted by researchers at the University of Bergen, Department of Clinical Medicine, showed that both bemcentinib and tilvestamab prevented